Literature DB >> 24898352

The feature of metabolic syndrome is a risk factor for biochemical recurrence after radical prostatectomy.

Masaki Shiota1, Akira Yokomizo, Ario Takeuchi, Kenjiro Imada, Keijiro Kiyoshima, Junichi Inokuchi, Katsunori Tatsugami, Seiji Naito.   

Abstract

BACKGROUND AND
OBJECTIVE: To examine the association between the features of metabolic syndrome (MetS) (obesity, hypertension, diabetes mellitus, and dyslipidemia) and the risk of biochemical recurrence (BCR) after radical prostatectomy in patients with prostate cancer.
METHODS: This study included 283 Japanese patients with localized prostate cancer who were treated with radical prostatectomy between 2008 and 2012. Their oncological outcomes and the prognostic significance of several clinicopathological factors, as well as the features of MetS, were analyzed.
RESULTS: Of 283 men who underwent radical prostatectomy, 49 (17.2%) subsequently developed BCR with a median postoperative follow-up of 14.8 months. Among the clinicopathological factors, prostate-specific antigen (PSA) level at diagnosis, pathological stage, pathological Gleason score, and lymph-node involvement were independent risk factors for BCR in multivariate analysis. In addition, the number of metabolic risk factors was also an independent risk factor for BCR.
CONCLUSIONS: The features of MetS were linked with poorer outcome after radical prostatectomy among Japanese men. Further investigations are needed to determine the effect of improving MetS on prostate cancer prognosis.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  metabolic syndrome; prostate cancer; radical prostatectomy; risk factor

Mesh:

Substances:

Year:  2014        PMID: 24898352     DOI: 10.1002/jso.23677

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  16 in total

1.  The Association of Diabetes and Obesity With Prostate Cancer Progression: HCaP-NC.

Authors:  Saira Khan; Jianwen Cai; Matthew E Nielsen; Melissa A Troester; James L Mohler; Elizabeth T H Fontham; Laura H Hendrix; Laura Farnan; Andrew F Olshan; Jeannette T Bensen
Journal:  Prostate       Date:  2017-03-06       Impact factor: 4.104

2.  Clinical factors affecting perioperative outcomes in robot-assisted radical prostatectomy.

Authors:  Tomohiko Murakami; Satoshi Otsubo; Ryo Namitome; Masaki Shiota; Junichi Inokuchi; Ario Takeuchi; Eiji Kashiwagi; Katsunori Tatsugami; Masatoshi Eto
Journal:  Mol Clin Oncol       Date:  2018-09-13

3.  Oxidized low-density lipoprotein is associated with advanced-stage prostate cancer.

Authors:  Fangning Wan; Xiaojian Qin; Guiming Zhang; Xiaolin Lu; Yao Zhu; Hailiang Zhang; Bo Dai; Guohai Shi; Dingwei Ye
Journal:  Tumour Biol       Date:  2015-01-08

4.  Obesity at Diagnosis and Prostate Cancer Prognosis and Recurrence Risk Following Primary Treatment by Radical Prostatectomy.

Authors:  Crystal S Langlais; Janet E Cowan; John Neuhaus; Stacey A Kenfield; Erin L Van Blarigan; Jeanette M Broering; Matthew R Cooperberg; Peter Carroll; June M Chan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-08-28       Impact factor: 4.254

5.  Metabolic syndrome, dyslipidemia and prostate cancer recurrence after primary surgery or radiation in a veterans cohort.

Authors:  L C Macleod; L J Chery; E Y C Hu; S B Zeliadt; S K Holt; D W Lin; M P Porter; J L Gore; J L Wright
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-03-31       Impact factor: 5.554

6.  The prognostic impact of serum testosterone during androgen-deprivation therapy in patients with metastatic prostate cancer and the SRD5A2 polymorphism.

Authors:  M Shiota; N Fujimoto; A Yokomizo; A Takeuchi; E Kashiwagi; T Dejima; K Kiyoshima; J Inokuchi; K Tatsugami; M Eto
Journal:  Prostate Cancer Prostatic Dis       Date:  2016-02-09       Impact factor: 5.554

Review 7.  Meta-analysis of metabolic syndrome and prostate cancer.

Authors:  M Gacci; G I Russo; C De Nunzio; A Sebastianelli; M Salvi; L Vignozzi; A Tubaro; G Morgia; S Serni
Journal:  Prostate Cancer Prostatic Dis       Date:  2017-02-21       Impact factor: 5.554

8.  Metabolic Syndrome, as Defined Based on Parameters Including Visceral Fat Area, Predicts Complications After Surgery for Rectal Cancer.

Authors:  Chong-Jun Zhou; Yi-Fan Cheng; Lin-Zhen Xie; Wan-Le Hu; Bo Chen; Lei Xu; Chong-Jie Huang; Mao Cai; Xian Shen; Chang-Bao Liu
Journal:  Obes Surg       Date:  2020-01       Impact factor: 4.129

9.  Secondary bladder cancer after anticancer therapy for prostate cancer: reduced comorbidity after androgen-deprivation therapy.

Authors:  Masaki Shiota; Akira Yokomizo; Ario Takeuchi; Kenjiro Imada; Keijiro Kiyoshima; Junichi Inokuchi; Katsunori Tatsugami; Saiji Ohga; Katsumasa Nakamura; Hiroshi Honda; Seiji Naito
Journal:  Oncotarget       Date:  2015-06-10

10.  The Prevalence of Cardiac Risk Factors in Men with Localized Prostate Cancer Undergoing Androgen Deprivation Therapy in British Columbia, Canada.

Authors:  Margot K Davis; Jennifer L Rajala; Scott Tyldesley; Tom Pickles; Sean A Virani
Journal:  J Oncol       Date:  2015-08-02       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.